替罗非班用于急性冠脉综合征的临床效果及安全性分析

Clinical Effect and Safety Analysis of Tirofiban in the Treatment of Acute Coronary Syndrome

目的:探讨替罗非班治疗急性冠脉综合征的临床效果及安全性。方法:整层抽样法抽取80例急性冠脉综合征患者,随机双盲法分为观察组(n=40)与参考组(n=40),两组接受常规治疗,观察组同时接受替罗非班治疗,比较不良心血管事件发生次数、心功能改善指标及不良反应发生率。结果:观察组心绞痛发作次数明显少于参考组(P<0.05);治疗后,观察组左室射血分数(LVEF)、室间隔厚度(LVST)、左房内径(LAD)、肺动脉高压(PH)及肌酸激酶同工酶(CK-MB)与治疗前比较明显改善,且改善程度大于参考组(P<0.05);两组不良反应发生率比较无统计学意义(P>0.05)。结论:替罗非班用于急性冠脉综合征治疗中,可显著改善心功能,增加心肌供血,减轻心绞痛等症状,安全可靠。

Objective: To explore the clinical effect and safety of tirofiban in the treatment of acute coronary syndrome. Methods: A total of 80 patients with acute coronary syndrome were selected by the whole layer sampling method, and randomly divided into the observation group ( n =40) and the reference group ( n =40), both groups received conventional treatment, while the observation group received tirofiban at the same time. The frequency of adverse cardiovascular events, the index of cardiac function improvement and the incidence of adverse reactions were compared. Results: The number of angina attack in the observation group was significantly less than that in the reference group ( P <0.05). After treatment, the left ventricular ejection fraction (LVEF), ventricular septal thickness (LVST), left atrial diameter (LAD), pulmonary hypertension (PH) and creatine kinase isoenzyme (ck-mb) in the observation group were significantly improved compared with those before treatment, and the improvement degree was greater than that in the reference group ( P <0.05);There was no significant difference in the incidence of adverse reactions between the two groups ( P >0.05). Conclusion: In the treatment of acute coronary syndrome, tirofiban can significantly improve cardiac function, increase myocardial blood supply, reduce angina and other symptoms, and is safe and reliable.